CD47 and glioblastoma: Since the recent identification of CD47/SIRPα axis as a therapeutic target for human solid tumors [90–92], there have been several preclinical studies examining the safety and efficacy of targeting CD47 as an immune checkpoint molecule for GBM therapy [93, 94].